Pancreatic Cancer

New treatment combination containing irinotecan shows promising survival rate

Published in Cancer Weekly, April 2nd, 2002

The combination of irinotecan (CPT-11) and gemcitabine shows promise in treating pancreatic cancer, a disease with a very high mortality rate compared with other forms of cancer.

This combination treatment demonstrated a one-year survival rate of 27%, which is greater than that reported with gemcitabine alone in previous studies of patients with advanced pancreatic cancer (15% and 18% 1-year survival rates, respectively). This new study finding has been published in the March 2002 issue of the Journal of Clinical Oncology.

"The findings suggest that the addition of irinotecan to gemcitabine may enhance the clinical benefit of gemcitabine as...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-04-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry